Longevity medicine is moving from a focus on preventing specific diseases to a broader framework of targeting the biological mechanisms of ageing itself. Within this framework, therapeutic peptides occupy an increasingly prominent position, both as licensed pharmaceuticals and as research-stage compounds being explored by patients and practitioners in advance of full clinical validation. Understanding the landscape requires distinguishing between the well-evidenced, the promising but preliminary, and the speculative.
Growth Hormone Secretagogues for Body Composition and Recovery
The best-evidenced therapeutic peptides for adult longevity applications are growth hormone secretagogues including Sermorelin, CJC-1295, and Ipamorelin. The evidence for their effects on visceral fat reduction, lean mass preservation, and sleep quality is derived from multiple human clinical studies and aligns with the well-established effects of GH on these parameters. For adults over 40 experiencing the body composition changes and recovery impairment associated with age-related GH decline, this class of peptides has the most robust human clinical evidence of any longevity-targeted peptide application.
Tissue Repair Peptides
BPC-157 and TB-500 have the most extensive preclinical evidence base for tissue repair acceleration among research peptides. The human evidence remains limited to case series and anecdotal reports, but the mechanistic evidence, multiple independent animal studies from different research groups, and the apparent safety profile of BPC-157 make it one of the more credible research peptide applications for athletes, active individuals, and anyone managing chronic musculoskeletal conditions. The Wolverine blend category combines these compounds specifically for injury recovery and accelerated healing.
Skin and Extracellular Matrix Peptides
GHK-Cu has the strongest evidence base in the skin health peptide category, with both extensive in vitro data and human clinical studies demonstrating effects on collagen production and skin architecture. The Glow blend category targeting skin quality typically centres on GHK-Cu, often combined with epithalon for its broader anti-ageing effects, and sometimes with DSIP or other sleep-improving peptides, as sleep quality is one of the most potent determinants of skin appearance. Dietary collagen peptides, specifically hydrolysed Type I and III collagen, have their own randomised trial evidence for improving skin hydration and elasticity.
Longevity-Targeted Peptides: Epithalon and Thymosin Alpha-1
For peptides specifically targeted at biological ageing mechanisms, Epithalon has the most extensive published research, primarily from Khavinson's group, showing effects on telomerase activation, pineal function, and longevity biomarkers in animal models and observational human studies. Thymosin Alpha-1 has the strongest human clinical evidence of any immune-targeted peptide, with a licensed pharmaceutical status in over 35 countries and randomised trial evidence for its effects on viral infections, cancer immunity, and potentially COVID-19 outcomes. Both are relevant to the immune ageing dimension of longevity medicine.
Working Within a Longevity Framework
Peptide therapy for longevity achieves its greatest benefit when implemented within a comprehensive longevity framework that addresses sleep, nutrition, exercise, stress management, and metabolic health. Peptides do not substitute for these foundational interventions; they augment them. The assessment of biological age, through epigenetic clocks, biological age testing, and comprehensive metabolic markers, provides the baseline against which peptide intervention effects can be measured. At Zhen Wellness, the Apex Programme provides the clinical framework within which peptide therapy, where appropriate, can be incorporated alongside the foundational longevity interventions that the research most consistently supports.